Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Daniel, Peter Prof. Dr. (1) Hübner, Norbert Prof. Dr. (17) Janz, Martin Dr. (4) Langanki, Reika (1) Lee, Young-Ae Prof. Dr. (3) Leisegang, Matthias Prof. Dr. rer. nat. (1) Lusatis, Simone (1) Maatz, Henrike Dr. (1) Marenholz, Ingo Dr. (1) Mathas, Stephan Dr. (4) Saar, Kathrin Dr. (2) Uckert, Wolfgang Prof. Dr. (1) Walther, Wolfgang Prof. Dr. (1) (-) Blankenstein, Thomas Prof. Dr. (9) (-) Wollert-Wulf, Brigitte (2) (-) Biologie maligner Lymphome (2) (-) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (9) Proteom Dynamik (2) 1992 (4) 1993 (7) 1994 (5) (-) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) (-) 2006 (3) 2007 (5) 2008 (5) 2009 (2) 2010 (7) 2011 (5) 2012 (6) 2013 (13) 2014 (4) 2015 (5) 2016 (4) 2017 (6) 2018 (4) 2019 (7) 2021 (4) 2022 (6) 2023 (6) 2024 (3) 11 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Wollert-Wulf, BrigitteBiologie maligner LymphomeGenetik und Genomik von Herz- KreislauferkrankungenMolekulare Immunologie und Gentherapie 19952006 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. Januar 1995 / Canc Gene Ther Vectors in cancer therapy: how will they deliver M. Blaese T. Blankenstein M. Brenner O. Cohen-Haguenauer B. Gansbacher S. Russell B. Sorrentino T. Velu 01. Januar 1995 / Blood Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice Z. Qin L.J.H. van Tits W.A. Buurman T. Blankenstein 01. Januar 1995 / J Immunol IL-10 converts mouse lymphoma cells to a CTL-resistant, nk-sensitive phenotype with low but peptide-inducible MHC class I expression F. Salazar-Onfray M. Petersson L. Franksson M. Matsuda T. Blankenstein K. Karre R. Kiessling 01. Januar 1995 / Eur J Immunol Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines S. Cayeux C. Beck A. Aicher B. Doerken T. Blankenstein 01. Januar 1995 / Eur J Cancer European school of oncology position paper - gene therapy for the medical oncologist M. Blaese T. Blankenstein M. Brenner O. Cohenhaguenauer B. Gansbacher B. Sorrentino T. Velu 01. Januar 1995 / Hum Gene Ther The thymidine kinase/ganciclovir-mediated "suicide" effect is highly variable in different tumor cells C. Beck S. Cayeux S. Lupton B. Doerken T. Blankenstein 01. Januar 1995 / Canc Res Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response Z. Qin T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. Januar 1995 / Canc Gene Ther Vectors in cancer therapy: how will they deliver M. Blaese T. Blankenstein M. Brenner O. Cohen-Haguenauer B. Gansbacher S. Russell B. Sorrentino T. Velu
01. Januar 1995 / Blood Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice Z. Qin L.J.H. van Tits W.A. Buurman T. Blankenstein
01. Januar 1995 / J Immunol IL-10 converts mouse lymphoma cells to a CTL-resistant, nk-sensitive phenotype with low but peptide-inducible MHC class I expression F. Salazar-Onfray M. Petersson L. Franksson M. Matsuda T. Blankenstein K. Karre R. Kiessling
01. Januar 1995 / Eur J Immunol Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines S. Cayeux C. Beck A. Aicher B. Doerken T. Blankenstein
01. Januar 1995 / Eur J Cancer European school of oncology position paper - gene therapy for the medical oncologist M. Blaese T. Blankenstein M. Brenner O. Cohenhaguenauer B. Gansbacher B. Sorrentino T. Velu
01. Januar 1995 / Hum Gene Ther The thymidine kinase/ganciclovir-mediated "suicide" effect is highly variable in different tumor cells C. Beck S. Cayeux S. Lupton B. Doerken T. Blankenstein
01. Januar 1995 / Canc Res Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response Z. Qin T. Blankenstein